High SLC20A1 expression is associated with poor prognoses in claudin-low and basal-like breast cancers

CHOTARO ONAGA, SHOMA TAMORI, HITOMI MOTOMURA, AYAKA OZAKI, CHIKA MATSUDA, IZUMI MATSUOKA, TAKUMA FUJITA, YUKA NOZAKI, YASUSHI HARA, YOHEI KAWANO, Yohsuke Harada, TSUGUMICHI SATO, YASUNARI MANO, KEIKO SATO, KAZUNORI AKIMOTO

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: SLC20A1 has been identified as a prognostic marker in ER+ breast cancer. However, the role of SLC20A1 expression in breast cancer subtypes other than the ER+ types remains unclear. Materials and Methods: Genomics datasets were downloaded and analyzed, and the effect of SLC20A1 knockdown using targeted siRNA on cell viability and tumor-sphere formation was assessed. Results: SLC20A1high patients with ER+, claudin-low or basal-like breast cancers showed poor prognoses. SLC20A1high patients treated with radiotherapy had poor clinical outcomes. SLC20A1 knockdown suppressed the viability of MDA-MB 231 (claudin-low), MDA-MB 468 (basal-like) and MCF-7 (ER+) cells, and tumor-sphere formation by ALDH1high cells. These results suggest that SLC20A1 is involved in cancer progression and contributes to clinical outcomes in patients with ER+, claudin-low and basal-like breast cancers. Conclusion: SLC20A1 is a potential prognostic marker and therapeutic target in ER+, claudin-low and basal-like breast cancers.

Original languageEnglish
Pages (from-to)43-54
Number of pages12
JournalAnticancer research
Volume41
Issue number1
DOIs
Publication statusPublished - Jan 2021

Keywords

  • ALDH1
  • Basal-like
  • Breast cancer
  • Cancer stem cell
  • Claudin-low
  • Prognostic marker
  • SLC20A1

Fingerprint Dive into the research topics of 'High SLC20A1 expression is associated with poor prognoses in claudin-low and basal-like breast cancers'. Together they form a unique fingerprint.

Cite this